Takeda Pharmaceutical マネジメント

マネジメント基準チェック /44

Takeda Pharmaceuticalの CEO はChristophe P. Weberで、 Jun2014年に任命され、の在任期間は 11.92年です。の年間総報酬は¥ 2.16Bで、 15.6%給与と84.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.055%を直接所有しており、その価値は$ 28.16M 。経営陣と取締役会の平均在任期間はそれぞれ5年と9.9年です。

主要情報

Christophe P. Weber

最高経営責任者

JP¥2.2b

報酬総額

CEO給与比率	15.59%
CEO在任期間	11.9yrs
CEOの所有権	0.05%
経営陣の平均在職期間	5yrs
取締役会の平均在任期間	9.9yrs

経営陣の近況

Recent updates

CEO報酬分析

Takeda Pharmaceutical の収益と比較して、Christophe P. Weber の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2026	n/a	n/a	JP¥192b
Dec 31 2025	n/a	n/a	JP¥113b
Sep 30 2025	n/a	n/a	JP¥33b
Jun 30 2025	n/a	n/a	JP¥137b
Mar 31 2025	JP¥2b	JP¥337m	JP¥108b
Dec 31 2024	n/a	n/a	JP¥208b
Sep 30 2024	n/a	n/a	JP¥290b
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥2b	JP¥317m	JP¥144b
Dec 31 2023	n/a	n/a	JP¥178b
Sep 30 2023	n/a	n/a	JP¥192b
Jun 30 2023	n/a	n/a	JP¥301b
Mar 31 2023	JP¥2b	JP¥295m	JP¥317b
Dec 31 2022	n/a	n/a	JP¥275b
Sep 30 2022	n/a	n/a	JP¥213b
Jun 30 2022	n/a	n/a	JP¥197b
Mar 31 2022	JP¥2b	JP¥281m	JP¥230b
Dec 31 2021	n/a	n/a	JP¥439b
Sep 30 2021	n/a	n/a	JP¥473b
Jun 30 2021	n/a	n/a	JP¥431b
Mar 31 2021	JP¥2b	JP¥267m	JP¥376b
Dec 31 2020	n/a	n/a	JP¥181b
Sep 30 2020	n/a	n/a	JP¥56b
Jun 30 2020	n/a	n/a	JP¥120b
Mar 31 2020	JP¥2b	JP¥273m	JP¥44b

報酬と市場: Christophe P.の総報酬 ($USD 13.60M ) は、 US市場 ($USD 14.80M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Christophe P.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Christophe P. Weber (59 yo)

11.9yrs

在職期間

JP¥2,161,000,000

報酬

Mr. Christophe P. Weber serves as Chief Executive Officer at Takeda Pharmaceutical Company Limited since April 2015 and as President and Representative Director since June 2014. He joined the firm on April...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christophe P. Weber	President	11.9yrs	JP¥2.16b	0.055% $ 28.2m
Milano Furuta	CFO & Director	2.1yrs	JP¥302.00m	0.0019% $ 999.0k
Andrew S. Plump	President of Research & Development and Representative Director	no data	JP¥1.20b	0.020% $ 10.2m
Seigo Izumo	Chair of Management Board	no data	データなし	データなし
Haruhiko Hirate	Member of Management Board	no data	データなし	データなし
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	データなし	データなし
Michael Fox	Chief Operating Officer	no data	データなし	データなし
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	データなし	データなし
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	13.2yrs	データなし	データなし
Gabriele Ricci	Chief Data & Technology Officer	4.3yrs	データなし	0.0025% $ 1.3m
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	5.7yrs	データなし	データなし
Natalie Furney	Global General Counsel	1.3yrs	データなし	データなし

5.0yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: TKPH.Fの経営陣は経験豊富であると考えられます ( 5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Christophe P. Weber	President	11.9yrs	JP¥2.16b	0.055% $ 28.2m
Milano Furuta	CFO & Director	no data	JP¥302.00m	0.0019% $ 999.0k
Andrew S. Plump	President of Research & Development and Representative Director	10.9yrs	JP¥1.20b	0.020% $ 10.2m
John Michael Maraganore	Independent External Director	3.9yrs	JP¥43.00m	0.00024% $ 123.6k
Steven S. Gillis	Independent External Director	7.3yrs	JP¥49.00m	0.00050% $ 257.5k
Emiko Higashi	Independent External Director	9.9yrs	JP¥50.00m	0.00056% $ 288.4k
Yoshiaki Fujimori	Independent External Director	9.9yrs	JP¥40.00m	0.0012% $ 633.4k
Ian T. Clark	Independent External Director	7.3yrs	JP¥49.00m	0.00031% $ 159.6k
Jean-Luc Butel	Independent External Director	6.9yrs	JP¥51.00m	0.00024% $ 123.6k
Michel Orsinger	Independent External Director	9.9yrs	JP¥53.00m	0.00024% $ 123.6k
Masami Iijima	Independent External Chair	4.9yrs	JP¥43.00m	0.00041% $ 211.1k
Koji Hatsukawa	Independent External Director	9.9yrs	JP¥42.00m	0.00054% $ 278.1k

9.9yrs

平均在職期間

67.5yo

平均年齢

経験豊富なボード: TKPH.Fの取締役会は経験豊富であると考えられます ( 9.9年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/21 00:47
終値	2026/05/21 00:00
収益	2026/03/31
年間収益	2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Takeda Pharmaceutical Company Limited 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。27

アナリスト	機関
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Takeda Pharmaceutical マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Announces Executive Changes, Effective June 2026

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Recent updates

Takeda Pharmaceutical Company Limited to Report Q2, 2027 Results on Oct 29, 2026

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease

Takeda Pharmaceutical Company Limited Announces Zasocitinib Delivers Rapid and Durable Skin Clearance in Plaque Psoriasis

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Takeda Pharmaceutical Company Limited to Report Q1, 2027 Results on Jul 30, 2026

Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera

Takeda Announces Positive Phase 3 Data Demonstrate Potential for ENTYVIO®? (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year 2025

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda Pharmaceutical Company Limited to Report Q3, 2026 Results on Jan 29, 2026

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V

Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025

Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation

Takeda Announces Executive Changes, Effective June 2026

Takeda Presents Orexin Data from Landmark Oveporexton Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda Announces U.S. FDA Approves Expanded Indication for VONVENDI for Adults and Children with Von Willebrand Disease

Takeda Pharmaceutical Company Limited to Report Q2, 2026 Results on Oct 30, 2025

Takeda Pharmaceutical Company Limited Announces an Embargoed Version of an Abstract for Phase 3 TAK-861-3002 Study (Radiantlight) of Oveporexton (TAK-861) in Narcolepsy Type 1, Which Is Slated to Be Presented At the Upcoming World Sleep 2025 Congress

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2025

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHub Duo Devices to Simplify HYQVIA Administration

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Approves Dividend

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Takeda Pharmaceutical Company Limited (TSE:4502) announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

マネジメント基準チェック /44